Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Table 1

Laboratory results of the patient at admission and at discharge from our hospital.

Blood analysis (reference ranges)	At admission	At discharge
Hemoglobin (120–160 g/l)	105 g/l	109 g/l
Leucocytes (4.0–10.0 G/l)	7.2 G/l	5.8 G/l
Eosinophils (0–0.7 G/l)	0.36 G/l	—
Lymphocytes (1.0–4.0 G/l)	0.11 G/l	—
Platelets (150–300 G/l)	156 G/l	317 G/l
Urea (2.8–7.0 mmol/)	23.2 mmol/l	9.7 mmol/l
Creatinine (50–95 µmol/l)	215 µmol/l	86 µmol/l
Sodium (136–146 mmol/l)	133 mmol/l	139 mmol/l
Potassium (3.7–5.0 mmol/l)	4.1 mmol/l	4.2 mmol/l
Albumin (37–51 g/l)	30.2 g/l	—
Aspartate transaminase (<44 U/l)	77 U/l	48 U/l
Alanine aminotransferase (<44 U/l)	70 U/l	58 U/l
Alkaline phosphatase (35–105 U/l)	107 U/l	75 U/l
Gamma-glutamyl transferase (<40 U/l)	54 U/l	40 U/l
Total bilirubin (3.1–18.8 µmol/l)	25.7 µmol/l	14.3 µmol/l
Direct bilirubin (<3.4 µmol/l)	19.6 µmol/l	9.7 µmol/l
Prothrombin time % (75–100%)	34%	69%
Partial thromboplastin time (26–36 sec)	58 sec	—
Factor VII (70–120%)	66%	—
Creatinine kinase (<170 U/l)	210 U/l	—
C-reactive protein (<5 mg/l)	129 mg/l	24 mg/l